Biomarker & Intervention Discovery
Cervical Cancer
Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.
US DALYs227.1KWHO GHE 2021 · all ages
Global DALYs11.95MWHO GHE 2021 · worldwide
US mortality6,640 deaths/yrWHO GHE 2021
Global mortality337.9K deaths/yrWHO GHE 2021 · worldwide
NIH funding$135MFY2025 · RCDC estimate
Funding levelWell-Funded
Spontaneous remissionCIN2/3 (precancerous): spontaneous regression in 40-60% of CIN2 without treatment; CIN3: regression in ~30%; invasive…
Best-intervention remissionEarly-stage (IA-IIA): radical hysterectomy or chemoradiation — 80-90% 5-year survival; locally advanced (IIB-IVA):…
Gap sizeVery large from a prevention standpoint — HPV vaccination and screening can prevent most cervical cancers but coverage…
Primary barrieraccess (prevention)
Full remission profile →
Remission & chronicity
Spontaneous remission
CIN2/3 (precancerous): spontaneous regression in 40-60% of CIN2 without treatment; CIN3: regression in ~30%; invasive cervical cancer: no spontaneous regression
Best-intervention remission
Early-stage (IA-IIA): radical hysterectomy or chemoradiation — 80-90% 5-year survival; locally advanced (IIB-IVA): cisplatin-based chemoradiation — 60-70% 5-year survival; metastatic with pembrolizumab + chemotherapy ± bevacizumab: 24.4 vs 16.3 months OS (KEYNOTE-826); ENGOT-cx11/GOG-3047: cemiplimab + chemo superior
Gap size
Very large from a prevention standpoint — HPV vaccination and screening can prevent most cervical cancers but coverage is dramatically insufficient
Primary barrier
access (prevention)
HPV vaccination prevents ~90% of cervical cancers caused by HPV 16/18 (and gardasil 9 covers 9 types); cervical cancer screening (Pap + HPV co-testing) prevents invasive cancer; yet globally only 10% of women in LMICs have received the HPV vaccine; in the US, HPV vaccination coverage remains at ~60% of adolescents
Biomarker Targets & Therapeutic Agents
Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC.
Agents ranked: ● Clinical >
● Mechanistic >
● Correlative.
Pipeline results not yet available. Run: python -m biomarker_pipeline.run_for_diseases --skip-llm
Clinical Trials
Recruiting and recently completed trials from ClinicalTrials.gov.
Data retrieved 2026-07-06.
No recent clinical trials found on ClinicalTrials.gov for this condition.
Agents Found By Disease-Level Search
Searched directly from “Cervical Cancer” via ClinicalTrials.gov interventions and Open Targets'
disease→drug data — independent of the 0-gene target panel above.
This surfaces agents whose mechanism doesn't route through a curated gene (combination
therapies, standard-of-care drugs, targets outside the panel).
Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."